pharmaphorum August 17, 2021
Formedix

Over the past two years, the pharma industry’s demand for automated research solutions has increased significantly and, particularly when it comes to clinical trial design, the need has never been greater.

This shift to digitised approaches has been triggered by some persistent challenges faced by those companies still reliant on applying manual processes.

“A few common challenges appear time and time again when we speak with organisations about clinical trials,” Kevin Burges, head of product management at Formedix, explains.

“The first is a lack of standardisation in trial design, which leads to delays in study setup. Metadata is often not stored centrally or controlled effectively. And because it’s not standardized it can’t be reused, which means that each trial needs...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Shares of Hims & Hers Health surge 30% after startup says it will offer GLP-1 injections
AstraZeneca unveils plan for $1.5bn ADC plant in Singapore
Flexibility of alternative trial designs crucial for cell and gene therapy research
Therapies designed to dismantle cancer’s escape mechanisms show promise for patients
Unlocking Transparency in PBM Pricing

Share This Article